ReNetX Bio’s NoGo Trap therapeutic has been given “fast track” status by the Food and Drug Administration. The firm’s mission statement is clear and precise: “to boldly advance first-in-class therapeutics for people living with currently incurable neurological disorders.”
The injected therapeutic has shown promise in primates leading to a rare human trial using patients with chronic spinal cord injuries.